Association between Staphylococcus aureus colonization and clinical improvement in pediatric atopic dermatitis treated with dupilumab: a pilot study - Takeaways - MDSpire

Association between Staphylococcus aureus colonization and clinical improvement in pediatric atopic dermatitis treated with dupilumab: a pilot study

  • By

  • Cristiana Indolfi

  • Angela Klain

  • Giulio Dinardo

  • Simone Colosimo

  • Serena Ferrara

  • Carolina Grella

  • Massimiliano Galdiero

  • Anna De Filippis

  • Valentina Fiore

  • Michele Miraglia del Giudice

  • May 18, 2026

  • 0 min

Share

  • 1

    Dupilumab significantly improves clinical outcomes in children with moderate-to-severe atopic dermatitis, as evidenced by reductions in EASI and C-DLQI scores.

  • 2

    At 12 months, dupilumab-treated children showed no skin S. aureus colonization, contrasting with 80% of those receiving conventional therapy.

  • 3

    Nasal S. aureus colonization was lower in dupilumab-treated patients compared to those on conventional therapy, indicating a potential microbiological benefit.

  • 4

    The study highlights dupilumab's good tolerability and sustained clinical benefits over 12 months in managing atopic dermatitis.

  • 5

    Microbiological findings from this pilot study should be interpreted cautiously due to the small sample size and exploratory nature of the research.

Original Source(s)

Related Content